

JOHAN ASKLING PUBLICATIONS 2015**Peer reviewed articles**

Arkema EV, Jonsson J, Baecklund E, Bruchfeld J, Feltelius N, Askling J, Grp AS. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? *Annals of the Rheumatic Diseases* 2015; 74: 1212-1217.

Baker N, Frisell T, Askling J, Kawabata H, Simon TA. Comparison of Patients Initiating Abatacept and TNFs Enrolled in MarketScan and the ARTIS Registry. *Pharmacoepidemiology and Drug Safety* 2015; 24: 54-54.

Bengtsson K, Forsblad-d'Elia H, Lie E, Klingberg E, Dehlin M, Exarchou S, Lindstrom U, Askling J, Jacobsson LTH. Increased Risk of Atrioventricular Block, Atrial Fibrillation and Pacemaker Implantation in Ankylosing Spondylitis, Undifferentiated Spondylarthritis and Psoriatic Arthritis Compared to the General Population. *Arthritis & Rheumatology* 2015; 67.

Bengtsson K, Forsblad-d'Elia H, Lie E, Klingberg E, Dehlin M, Exarchou S, Lindstrom U, Askling J, Jacobsson LTH. Are Ankylosing Spondylitis, Psoriatic Arthritis and Undifferentiated Spondylarthritis Associated with an Increased Risk of Cardiovascular Disease? *Arthritis & Rheumatology* 2015; 67.

Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R, Grp A. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. *Annals of the Rheumatic Diseases* 2015; 74: 890-896.

Chatzidionysiou K, Kristensen LE, Eriksson J, Askling J, van Vollenhoven R, Grp A. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register. *Scandinavian Journal of Rheumatology* 2015; 44: 431-437.

Chatzidionysiou K, Reynisdottir G, Joshua V, Frisell T, Askling J, Catrina AI. Risk for Lung Cancer in RA and Different RA Phenotypes: Results from a Population-Based Case-Control Study. *Arthritis & Rheumatology* 2015; 67.

Di Giuseppe D, Bottai M, Askling J, Wolk A. Physical activity and risk of rheumatoid arthritis in women: a population-based prospective study. *Arthritis Research & Therapy* 2015; 17.

Eriksson JK, Johansson K, Askling J, Neovius M. Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed? *Annals of the Rheumatic Diseases* 2015; 74: 648-654.

Eriksson JK, Neovius M, Askling J, Grp AS. Does the Level of Disease Control Achieved with Biologics Influence Overall Costs for Health Care and Work Loss in RA? *Arthritis & Rheumatology* 2015; 67.

Exarchou S, Lindstrom U, Askling J, Eriksson JK, Forsblad-d'Elia H, Neovius M, Turesson C, Kristensen LE, Jacobsson LTH. The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. *Arthritis Research & Therapy* 2015; 17.

Fang F, Sveinsson O, Thormar G, Granqvist M, Askling J, Lundberg IE, Ye W, Hammarstrom L, Pirskanen R, Piehl F. The autoimmune spectrum of myasthenia gravis: a Swedish population-based study. *Journal of Internal Medicine* 2015; 277: 594-604.

Frisell T, Saevarsdottir S, Askling J. Do RA Susceptibility Loci Predict Response to Methotrexate As First DMARD in Early RA? *Arthritis & Rheumatology* 2015; 67.

Hellgren K, Sundstrom C, Askling J, Baecklund E, Grp AS. Lymphoma in Patients with Rheumatoid Arthritis Treated with Biologic Drugs: Long-Term Follow-up of Risks and Lymphoma Subtypes. *Arthritis & Rheumatology* 2015; 67.

Hensvold AH, Frisell T, Askling J, Catrina AI. How Well Do Acpas Discriminate and Predict RA in the General Population - a Study Based on 12,590 Population-Representative Swedish Twins. *Arthritis & Rheumatology* 2015; 67.

Hensvold AH, Magnusson PKE, Joshua V, Hansson M, Israelsson L, Ferreira R, Jakobsson PJ, Holmdahl R, Hammarstrom L, Malmstrom V, Askling J, Klareskog L, Catrina AI. Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins. *Annals of the Rheumatic Diseases* 2015; 74: 375-380.

Jakobsen AK, Jacobsson LTH, Patschan O, Hopfgarten T, Askling J, Kristensen LE. Surgical interventions for nephrolithiasis in ankylosing spondylitis and the general population. *Scandinavian Journal of Urology* 2015; 49: 486-491.

Jiang X, Frisell T, Askling J, Karlson EW, Klareskog L, Alfredsson L, Kallberg H. To What Extent Is the Familial Risk of Rheumatoid Arthritis Explained by Established Rheumatoid Arthritis Risk Factors? *Arthritis & Rheumatology* 2015; 67: 352-362.

Johansson K, Eriksson JK, van Vollenhoven R, Miller H, Askling J, Neovius M, Grp AS. Does disease activity at the start of biologic therapy influence health care costs in patients with RA? *Rheumatology* 2015; 54: 1472-1477.

Kearsley-Fleet L, Zavada J, Hetland ML, Nordstrom DC, Aaltonen KJ, Listing J, Zink A, Gati T, Rojkovich B, Iannone F, Gremese E, van Riel P, van de Laar M, Lie E, Kvien TK, Canhao H, Fonseca JE, Rotar Z, Loza E, Carmona L, Askling J, Johansson K, Finckh A, Dixon WG, Hyrich KL, Registers ESG. The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. *Rheumatology* 2015; 54: 1074-1079.

Knight A, Hjorton K, Sundstrom C, Hoglund M, Backlin C, Smedby KE, Askling J, Baecklund E. Leukemia and Myelodysplastic Syndrome in Granulomatosis with Polyangiitis: Subtypes, Clinical Characteristics, and Outcome. *Journal of Rheumatology* 2015; 42: 690-694.

Kristensen LE, Jakobsen AK, Askling J, Nilsson F, Jacobsson LTH. Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study. *Arthritis Care & Research* 2015; 67: 1137-1149.

Lie E, Kristensen LE, Forsblad-d'Elia H, Zverkova-Sandstrom T, Askling J, Jacobsson LT, Grp AS. The effect of comedication with conventional synthetic disease modifying

antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. *Annals of the Rheumatic Diseases* 2015; 74: 970-978.

Lie E, Lindstrom U, Zverkova-Sandstrom T, Olsen IC, Forsblad-d'Elia H, Askling J, Kristensen LE, Jacobsson LTH. The Effect of TNF Inhibitor Treatment on Occurrence of Anterior Uveitis in Ankylosing Spondylitis: Results from the Swedish Biologics Register. *Arthritis & Rheumatology* 2015; 67.

Lindstrom U, Exarchou S, Sigurdardottir V, Sundstrom B, Askling J, Eriksson JK, Forsblad-d'Elia H, Turesson C, Kristensen LE, Jacobsson L. Validity of ankylosing spondylitis and undifferentiated spondyloarthritis diagnoses in the Swedish National Patient Register. *Scandinavian Journal of Rheumatology* 2015; 44: 369-376.

Ljung L, Frisell T, Askling J. The Link Between DAS28 and the Short-Term Risk of Acute Coronary Syndrome in RA, and Its Driving Factors. *Arthritis & Rheumatology* 2015; 67.

Mantel A, Holmqvist M, Andersson D, Lund L, Askling J. Patients with Rheumatoid Arthritis Are at Increased Risk of Both Ischemic and Non-Ischemic Heart Failure. *Arthritis & Rheumatology* 2015; 67.

Mantel A, Holmqvist M, Jernberg T, Wallberg-Jonsson S, Askling J. Rheumatoid arthritis is associated with a more severe presentation of acute coronary syndrome and worse short-term outcome. *European Heart Journal* 2015; 36: 3413-3422.

Mantel A, Holmqvist M, Jernberg T, Wallberg-Jonsson S, Askling J. Secondary Preventive Pharmacotherapy and Longterm Outcomes Following Acute Coronary Events in Patients with Prevalent Rheumatoid Arthritis. *Arthritis & Rheumatology* 2015; 67.

Mantel A, Holmqvist M, Nyberg F, Tornling G, Frisell T, Alfredsson L, Askling J. Risk Factors for the Rapid Increase in Risk of Acute Coronary Events in Patients With New-Onset Rheumatoid Arthritis: A Nested Case-Control Study. *Arthritis & Rheumatology* 2015; 67: 2845-2854.

Mercer L, Askling J, Raaschou P, Dixon W, Dreyer L, Hetland M, Mellemkjaer L, Strangfeld A, Zink A, Iannone F, Finckh A, Zavada J, Canhao H, Martins F, Mariette X, Morel J, Gottenberg JE, Green A, Hernandez V, Tubach F, van Riel P, Hyrich KL, Listing J. RISK OF DEVELOPING A FIRST INVASIVE MELANOMA IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BIOLOGICS: RESULTS OF A COLLABORATIVE PROJECT OF 11 EUROPEAN BIOLOGICS REGISTERS. *Rheumatology* 2015; 54: 89-89.

Mercer L, Mariette X, Dixon W, Baecklund E, Hellgren K, Dreyer L, Hetland M, Mellemkjaer L, Hyrich K, Strangfeld A, Zink A, Canhao H, Martins F, Hernandez V, Tubach F, Gottenberg JE, Morel J, Zavada J, van Riel P, Finckh A, Iannone F, Askling J, Listing J. FIRST RESULTS OF A EUROPEAN REGISTRIES COLLABORATIVE PROJECT TO DESCRIBE THE SPECTRUM OF LYMPHOMAS ACROSS DIFFERENT DRUG TREATMENT GROUPS IN RHEUMATOID ARTHRITIS. *Rheumatology* 2015; 54: 25-25.

Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, Askling J, Grp AS. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. *Annals of the Rheumatic Diseases* 2015; 74: 354-360.

Nyberg F, Askling J, Berglind N, Franzen S, Ho ML, Holmqvist M, Horne L, Lampl K, Michaud K, Pappas DA, Reed G, Symmons D, Tanaka E, Tran TN, Verstappen SMM, Wesby-van Swaay E, Yamanaka H, Greenberg JD. Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. *Pharmacoepidemiology and Drug Safety* 2015; 24: 1121-1132.

Raaschou P, Frisell T, Askling J, Grp AS. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. *Annals of the Rheumatic Diseases* 2015; 74: 2137-2143.

Radner H, Dixon W, Hyrich K, Askling J. Consistency and Utility of Data Items Across European Rheumatoid Arthritis Clinical Cohorts and Registers. *Arthritis Care & Research* 2015; 67: 1219-1229.

Sparks JA, Chen CY, Jiang X, Askling J, Hiraki LT, Malspeis S, Klareskog L, Alfredsson L, Costenbader KH, Karlson EW. Improved performance of epidemiologic and genetic risk models for rheumatoid arthritis serologic phenotypes using family history. *Annals of the Rheumatic Diseases* 2015; 74: 1522-1529.

Verstappen SMM, Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Holmqvist M, Horne L, Lampl K, Michaud K, Nyberg F, Pappas DA, Reed G, Symmons DPM, Tanaka E, Tran TN, Yamanaka H, Ho ML. Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries. *Arthritis Care & Research* 2015; 67: 1637-1645.

Wadstrom H, Askling J, Grp AS. Risk of Cancer in Non-TNFi Biologics-Treated RA. *Arthritis & Rheumatology* 2015; 67.

Wadstrom H, Eriksson JK, Neovius M, Askling J, Grp AS. How good is the coverage and how accurate are exposure data in the Swedish Biologics Register (ARTIS)? *Scandinavian Journal of Rheumatology* 2015; 44: 22-28.